Searchable abstracts of presentations at key conferences in endocrinology

ea0065p219 | Metabolism and Obesity | SFEBES2019

Predicting mortality in both diabetes and open-source clinical datasets from free text entries using machine learning (natural language processing)

Sainsbury Christopher , Conkie Andrew , Buchner Mark , Wales Ann , Jones Gregory

Objective: We aimed to test the utility of semantic analysis to predict all-cause mortality from free-text entries from both a national diabetes database, and an open source clinical dataset (MIMIC-III). We analysed text entries alone, in order to fully understand the potential of language analysis to predict outcome.Method: Diabetes dataset: An analysis period of 3 years was defined during which clinical text data were extracted. Mortality status at 1 y...

ea0049gp104 | Diabetes therapy & complications 2 | ECE2017

Non-stimulated c-peptide is independently associated with requirement at 1 year for insulin therapy in patients with diabetes: a retrospective cohort study of 872 patients

Leighton Emma , Smith Karen , Sainsbury Christopher , Jones Gregory

Introduction: C-peptide is frequently used in clinical practice to estimate insulin secretion, and guide need for future insulin treatment. Present practice is based on studies with small patient numbers.Aim: To explore the association between non-stimulated c-peptide and progression to insulin therapy in patients with diabetes.Patients and Methods: 1971 patients with c-peptide measurements were identified (February 2007–Decem...

ea0041ep411 | Diabetes (to include epidemiology, pathophysiology) | ECE2016

Inpatient glycaemic variability and long-term mortality: a neglected diabetic parameter?

Timmons Joseph , Jones Gregory , Sainsbury Christopher , Cunningham Scott

Aim: To determine the association between recorded inpatient glycaemic variability and long-term mortality in patients with diabetes mellitus.Methods: Inpatient capillary blood glucose (CBG) readings from eight acute hospitals were included. Data was analysed from first admission within the dataset with >4 measured CBGs. 28 353 admissions were identified (24 181 type 2 DM, 4,172 type 1 DM). Matching parameters were: age, diabetes duration, admission ...

ea0038p93 | Clinical practice/governance and case reports | SFEBES2015

Evaluation of use of combination dapagliflozin and GLP1 agonist treatment in type 2 diabetes

Hayden Jennifer , Huang Feicong , McConnell Lyndsey , Sainsbury Christopher , Jones Gregory

Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. Whilst it has not been studied for use in combination with GLP1 agonists the modes of action of the two therapies suggest they would be a logical therapeutic combination. We aimed to evaluate clinical experience with this regimen.Methods: Observational retrospective data was collected from electronic patient records (SCI–diabetes) ...

ea0038p202 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Predictors of glycaemic response and impact on weight and BP of dapagliflozin therapy in type 2 diabetes

Huang Feicong , McConnell Lyndsey , Sainsbury Christopher , Jones Gregory

Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. The study aimed to assess impact of dapagliflozin on glucose, weight and BP and identify factors predictive of glycaemic response in a large cohort.Methods: Observational retrospective data collected on all patients prescribed dapagliflozin across primary and secondary care in two Scottish health board areas. HbA1c, weight, BP and conco...

ea0013p182 | Diabetes, metabolism and cardiovascular | SFEBES2007

Insulin treatment of patients with cystic fibrosis and impaired glucose tolerance arrests the decline in pulmonary function

Drummond Russell , Carty David , Small Michael , Jones Gregory

Critical clinical changes of pulmonary function and weight occur in patients with cystic fibrosis (CF) antecedent to the development of frank Diabetes Mellitus (DM). Impaired glucose tolerance (IGT) signifies diminished Insulin secretion and increased peripheral insulin resistance, correlating with worse clinical status, under nutrition and impaired pulmonary function. Insulin therapy has been associated with improvement in anthropometric data and an arrest in decline in force...

ea0013p184 | Diabetes, metabolism and cardiovascular | SFEBES2007

Incidence, awareness and apparent symptoms of hypoglycaemia in patients with cystic fibrosis treated with insulin

Drummond Russell , Carty David , Small Michael , Jones Gregory

Diabetes Mellitus (DM) and Impaired Glucose Tolerance (IGT) in patients with cystic fibrosis(CF) signifies a six fold rise in mortality and is associated with declining pulmonary function. The pathophysiology is multifactorial but largely due to Insulinopenia which is due to global islet cell fibrosis and accompanied by loss of islet alpha cells. Insulin treatment improves weight, the bacterial milieu, and lung function but is associated with hypoglycaemia. These patients may ...

ea0065p210 | Metabolism and Obesity | SFEBES2019

All cause and cardiovascular mortality in adults with schizophrenia and diabetes – a retrospective matched study

Morrison Deborah , Frize Ryan , Sainsbury Christopher A , Wilson Ruairi , Jones Gregory C

Introduction: Increased prevalence of diabetes is found in major psychosis, and poorer outcomes occur when both diagnoses co-exist. The aim of this study was to describe the association between total and cardiovascular mortality in people with both schizophrenia and diabetes, compared to diabetes alone.Materials and methods: Data was linked from the Glasgow Psychosis Clinical Information System (PsyCIS), the Scottish national diabetes database (SCI-Diabe...

ea0025oc2.8 | Steroids | SFEBES2011

Metformin increases in vivo 11β-hydroxysteroid dehydrogenase type 1 activity in euglycaemic obese men

Stimson Roland , Andrew Ruth , Jones Gregory , Livingstone Dawn , Smith Kenneth , Walker Brian

Inhibiting cortisol regeneration by 11β-HSD1 is a promising therapy for type two diabetes. In obesity, 11β-HSD1 activity is increased in adipose tissue but decreased in the liver, the latter putatively mediated by hyperinsulinaemia. We tested whether insulin sensitisation with metformin regulates 11β-HSD1 activity in whole body and in liver in obesity.Five obese men (age 48±5 years, BMI 39.8±3.6 kg/m2) participated in ...